Research progress of rivaroxaban causing changes in platelet count and function

doi:10.3969/j.issn.1673-8640.2024.05.016

Abstract

Abstract:

Thrombotic disease seriously threatens human life and health，especially the normal function of cardiovascular and cerebrovascular diseases. The main strategy of treating thrombotic disease is to inhibit the initiation of coagulation mechanism and block thrombin activation. As a new oral anticoagulant，rivaroxaban can efficiently and accurately block thrombus waterfall formation，with targeting，low side effects and low bleeding risk，and it has been widely used in clinical practice recently. With the widespread clinical use of rivaroxaban，its effects on platelet（PLT） count and function begins to emerge. In this review，the changes in PLT count and function and the mechanism caused by rivaroxaban are summarized to facilitate the rational evaluation on the coagulation function of patients during medication.

Key words: Platelet count, Platelet aggregation, Platelet activation, P-selectin, Rivaroxaban

CLC Number:

R446.11

XIONG Tianhui, CHAI Kening, XIA Wei, QU Linlin. Research progress of rivaroxaban causing changes in platelet count and function[J]. Laboratory Medicine, 2024, 39(5): 504-509.

Figures/Tables 5

References 59

[1]	张帅, 陈卓, 王心意, 等. 血栓性疾病的中医共性病机探讨[J]. 中西医结合心脑血管病杂志, 2022, 20(3):555-557.
[2]	陈建伟. 《血栓性疾病国内外新诊断治疗学》出版:二聚体预测老年患者下肢深静脉血栓的价值及准确率分析[J]. 介入放射学杂志, 2022, 31(11):后插7.
[3]	马丽媛, 王增武, 樊静, 等. 《中国心血管健康与疾病报告2022》要点解读[J]. 中国全科医学, 2023, 26(32):3975-3994. DOI
[4]	国家卫生计生委合理用药专家委员会, 中国药师协会. 冠心病合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2018, 10(6):1-130.
[5]	张广求, 张美祥, 王树平. 新型口服抗凝药物适应证及指南推荐意见[J]. 实用心脑肺血管病杂志, 2018, 26(9):1-5.
[6]	王乔宇, 武明芬, 柳鑫, 等. 2021中国静脉血栓栓塞症防治抗凝药物的选用与药学监护指南[J]. 中国临床药理学杂志, 2021, 37(21):2999-3016.
[7]	KANURI S H, KREUTZ R P. Pharmacogenomics of novel direct oral anticoagulants:newly identified genes and genetic variants[J]. J Pers Med, 2019, 9(1):7.
[8]	刘晓辉, 宋景春, 张进华, 等. 中国抗血栓药物相关出血诊疗规范专家共识[J]. 解放军医学杂志, 2022, 47(12):1169-1179.
[9]	张君, 蔡卫民. 基因多态性与新型口服抗凝药个体化用药概述[J]. 中国药师, 2019, 22(12):2262-2266.
[10]	刘春妍, 沈纪中, 梅笛, 等. 利伐沙班群体药代动力学研究进展[J]. 中南药学, 2022, 20(3):623-626.
[11]	吴婷婷. 利伐沙班在非瓣膜性房颤患者中的群体药动学和药效学研究[D]. 福州: 福建医科大学, 2021.
[12]	李茜, 严思敏, 葛卫红, 等. 不同剂量利伐沙班对非瓣膜性房颤患者血栓栓塞与出血事件影响的研究[J]. 中南药学, 2021, 19(3):534-538.
[13]	HUANG H Y, LIN S Y, CHENG S H, et al. Effectiveness and safety of different rivaroxaban dosage regimens in patients with non-valvular atrial fibrillation:a nationwide,population-based cohort study[J]. Sci Rep, 2018, 8(1):3451.
[14]	任杰峰, 司全金. 不同方案利伐沙班防治高龄老年血栓栓塞疾病的有效性和安全性研究[J]. 中华老年心脑血管病杂志, 2018, 20(4):367-370.
[15]	PETZOLD T, THIENEL M, DANNENBERG L, et al. Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1[J]. Circ Res, 2020, 126(4):486-500. DOI PMID
[16]	PISTROSCH F, MATSCHKE J B, SCHIPP D, et al. Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk:a randomised trial to assess effects on endothelial function,platelet activation and vascular biomarkers[J]. Diabetologia, 2021, 64(12):2701-2712.
[17]	陈凯. 新型口服抗凝药对心房颤动患者PLT功能及凝血功能影响的研究[D]. 大连: 大连医科大学, 2019.
[18]	LENART-MIGDALSKA A, DRABIK L, KANICA-WIATR M, et al. Increased levels of platelets and endothelial-derived microparticles in patients with non-valvular atrial fibrillation during rivaroxaban therapy[J]. Clin Appl Thromb Hemost, 2021, 27:10760296211019465.
[19]	MIMA Y, SANGATSUDA Y, YASAKA M, et al. Acute thrombocytopenia after initiating anticoagulation with rivaroxaban[J]. Intern Med, 2014, 53(21):2523-2527.
[20]	焦保庭, 檀晓东, 张邵东. 参附注射液对腹部手术患者术后深静脉血栓发生及凝血功能的影响[J]. 中国处方药, 2020, 18(8):138-140.
[21]	柯森淼, 林炳基, 贺友生. 利伐沙班防治老年髋部骨折后下肢深静脉血栓的临床效果观察[J]. 临床合理用药杂志, 2020, 13(32):75-76.
[22]	宋麒麟. 益气活血化瘀法和利伐沙班对老年股骨干骨折患者术后高凝状态的影响[J]. 中国实用医药, 2019, 14(35):163-165.
[23]	卢蕾, 王亚萍, 黄璇, 等. PLT聚集率和凝血试验相关参数在危重烧伤患者中的变化及临床意义[J]. 临床与病理杂志, 2019, 39(12):2704-2709.
[24]	HERNANDEZ-JUAREZ J, ESPEJO-GODINEZ H G, MANCILLA-PADILLA R, et al. Effects of rivaroxaban on platelet aggregation[J]. J Cardiovasc Pharmacol, 2020, 75(2):180-184.
[25]	CAMMISOTTO V, CARNEVALE R, NOCELLA C, et al. Nox2-mediated platelet activation by glycoprotein(GP)VI:effect of rivaroxaban alone and in combination with aspirin[J]. Biochem Pharmacol, 2019, 163:111-118.
[26]	NEHAJ F, SOKOL J, IVANKOVA J, et al. First evidence:TRAP-induced platelet aggregation is reduced in patients receiving xabans[J]. Clin Appl Thromb Hemost, 2018, 24(6):914-919.
[27]	SOKOL J, NEHAJ F, IVANKOVA J, et al. First evidence:rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation[J]. J Thromb Thrombolysis, 2018, 46(3):393-398.
[28]	WAN H, YANG Y, ZHU J, et al. An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation:a comparison of dabigatran and rivaroxaban[J]. Blood Coagul Fibrinolysis, 2016, 27(8):882-885.
[29]	VOIGTLAENDER M, BECKMANN L, SCHULENKORF A, et al. Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model[J]. J Thromb Haemost, 2020, 18(12):3267-3279.
[30]	ELLER T, BUSSE J, DITTRICH M, et al. Dabigatran,rivaroxaban,apixaban,argatroban and fondaparinux and their effects on coagulation POC and platelet function tests[J]. Clin Chem Lab Med, 2014, 52(6):835-844.
[31]	VILAHUR G, GUTIÉRREZ M, ARZANAUSKAITE M, et al. Intracellular platelet signalling as a target for drug development[J]. Vascul Pharmacol, 2018, 111:22-25.
[32]	STEFANINI L, BERGMEIER W. RAP1-GTPase signaling and platelet function[J]. J Mol Med(Berl), 2016, 94(1):13-19.
[33]	VALET C, SEVERIN S, CHICANNE G, et al. The role of class Ⅰ,Ⅱ and Ⅲ PI 3-kinases in platelet production and activation and their implication in thrombosis[J]. Adv Biol Regul, 2016, 61:33-41.
[34]	LAURENT P A, SÉVERIN S, HECHLER B, et al. Platelet PI3Kβ and GSK3 regulate thrombus stability at a high shear rate[J]. Blood, 2015, 125(5):881-888.
[35]	苏蕊雅. 肝素联合替罗非班、比伐卢定两种抗凝方案对STEMI病人PCI术后MACE、出血事件及P-选择素水平的影响[J]. 中西医结合心脑血管病杂志, 2019, 17(24):4090-4093.
[36]	李泽, 李新刚, 沈素. P-选择素在血栓形成中的作用及P-选择素抑制剂的研究进展[J]. 中南药学, 2020, 18(2):276-279.
[37]	华晓东. PLT活化标志物检测在临床研究中的应用进展[J]. 天津药学, 2018, 30(4):58-62.
[38]	胡丽红, 俎德学, 刘桂菊, 等. CD62P、PAC-1和CD63在妊娠期肝内胆汁淤积症的表达及意义[J]. 中国卫生检验杂志, 2020, 30(6):688-691.
[39]	钟艳霞, 黄战军, 龚昌荣. 利伐沙班对非瓣膜性房颤患者P-选择素表达水平影响的研究[J]. 数理医药学杂志, 2020, 33(9):1327-1329.
[40]	王又和, 余奇玲. 利伐沙班对下肢静脉血栓患者血清缺氧诱导因子1α、P-选择素及肿瘤坏死因子α的影响简[J]. 中国医院用药评价与分析, 2016, 16(10):1329-1330.
[41]	宋彬彬, 温志国. 利伐沙班对下肢静脉血栓患者HIF-α、P-选择素及TNF-α的影响研究[J]. 中国生化药物杂志, 2015(7):82-84.
[42]	SCHULTZ N H, HOLME P A, BJØRNSEN S, et al. The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis[J]. Platelets, 2020, 31(1):43-47. DOI PMID
[43]	JANG G W, LEE J M, CHOI S W, et al. Vascular protective effects of new oral anticoagulants in patients with atrial fibrillation[J]. J Clin Med, 2021, 10(19):4332.
[44]	戴益, 许玉玲, 刘莹, 等. 组织因子微粒、内皮细胞微粒及PLT微粒在急性髓细胞白血病中检测意义[J]. 广西医科大学学报, 2022, 39(5):815-819.
[45]	赵霞. PLT减少与血液中微粒的临床检验结果[J]. 中国药物与临床, 2020, 20(20):3482-3483.
[46]	ZHANG Y, MA K L, GONG Y X, et al. Platelet microparticles mediate glomerular endothelial injury in early diabetic nephropathy[J]. J Am Soc Nephrol, 2019, 30(1):182.
[47]	PAPADAKIS E, SARIGIANNI M, TZIOMALOS K, et al. Oral contraceptives increase platelet microparticle levels in normal-weight women with polycystic ovary syndrome[J]. Hormones(Athens), 2020, 19(4):565-571.
[48]	于博文, 王雪, 胡艳红, 等. 内皮微粒对血管内皮细胞衰老的影响及机制研究[J]. 中国病理生理杂志, 2021, 37(5):825-833.
[49]	FENG S, CHEN J W, SHU X Y, et al. Endothelial microparticles:a mechanosensitive regulator of vascular homeostasis and injury under shear stress[J]. Front Cell Dev Biol, 2022, 10:980112.
[50]	YU X, XU J, LIU W, et al. Bubbles induce endothelial microparticle formation via a calcium-dependent pathway involving flippase inactivation and rho kinase activation[J]. Cell Physiol Biochem, 2018, 46(3):965-974. DOI PMID
[51]	DUARTE R C F, RIOS D R A, FIGUEIREDO E L, et al. Thrombin generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban[J]. J Thromb Thrombolysis, 2021, 51(1):47-57.
[52]	YAMANE S, AMANO H, ITO Y, et al. The role of thromboxane prostanoid receptor signaling in gastric ulcer healing[J]. Int J Exp Pathol, 2022, 103(1):4-12.
[53]	张海雄, 李文静, 王翡, 等. 血清同型半胱氨酸和血栓素B2水平与突发性聋的相关性研究[J]. 中国耳鼻咽喉头颈外科, 2019, 26(8):437-440.
[54]	BRAUNE S, KÜPPER J H, JUNG F. Effect of prostanoids on human platelet function:an overview[J]. Int J Mol Sci, 2020, 21(23):9020.
[55]	DANNENBERG L, M'PEMBELE R, MOURIKIS P, et al. Rivaroxaban reduces thromboxane induced platelet aggregation-the forgotten compass arm?[J]. Platelets, 2021, 32(8):1126-1128.
[56]	PIGNATELLI P, PASTORI D, BARTIMOCCIA S, et al. Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein Ⅵ shedding[J]. Pharmacol Res, 2016, 113(Pt A):484-489.
[57]	QIAO J, ARTHUR J F, GARDINER E E, et al. Regulation of platelet activation and thrombus formation by reactive oxygen species[J]. Redox Biol, 2018, 14:126-130. DOI PMID
[58]	AKBAR H, DUAN X, PIATT R, et al. Small molecule targeting the Rac1-NOX2 interaction prevents collagen-related peptide and thrombin-induced reactive oxygen species generation and platelet activation[J]. J Thromb Haemost, 2018, 16(10):2083-2096. DOI PMID
[59]	RICHARDS G A, THERON A, TINTINGER G, et al. The effects of dabigatran and rivaroxaban on markers of polymorphonuclear leukocyte activation[J]. Pharmaceuticals(Basel), 2018, 11(2):46.

参考文献	研究对象和用药方案	用药前PLT计数/（×10⁹/L）	用药后PLT计数/ （×10⁹/L）
[19]	1例服用利伐沙班的阵发性AF^①患者；10 mg·d^-1，连续服用21 d	168	37^*（7 d后）
[20]	60例腹部手术后服用利伐沙班患者；10 mg·d^-1，连续服用7 d	263.15±27.09	219.92±22.27^*（7 d后）
[21]	34例骨折手术后服用利伐沙班患者；10 mg·d^-1，连续服用5周	194.12±23.28	173.17±19.82^*（用药后）
[22]	24例股骨干骨折髓内钉固定术后服用利伐沙班患者；10 mg·d^-1，连续服用7 d	237.29±1.99	203.18±1.78^*（7 d后）

参考文献	研究对象和用药方案	用药前PLT计数/（×10⁹/L）	用药后PLT计数/ （×10⁹/L）
[19]	1例服用利伐沙班的阵发性AF^①患者；10 mg·d^-1，连续服用21 d	168	37^*（7 d后）
[20]	60例腹部手术后服用利伐沙班患者；10 mg·d^-1，连续服用7 d	263.15±27.09	219.92±22.27^*（7 d后）
[21]	34例骨折手术后服用利伐沙班患者；10 mg·d^-1，连续服用5周	194.12±23.28	173.17±19.82^*（用药后）
[22]	24例股骨干骨折髓内钉固定术后服用利伐沙班患者；10 mg·d^-1，连续服用7 d	237.29±1.99	203.18±1.78^*（7 d后）

参考文献	研究对象和用药方案	激活剂	用药前PAR^①/%	用药后 PAR^①/%
[26]	21例服用利伐沙班的NVAF患者；15 mg·qd^-1，连续服用≥18 d	TRAP	56.15	8.53^*（7 d后）
[27]	14例服用利伐沙班的NVAF患者；15 mg·qd^-1或20 mg·qd^-1，连续服用≥7 d	凝血酶	69.55±32.15	44.79±34.97^*（7 d后）
[28]	6名健康志愿者，与递增浓度的利伐沙班混合	TF	78.00±5.00	77.50±1.60^*体外试验

参考文献	研究对象和用药方案	激活剂	用药前PAR^①/%	用药后 PAR^①/%
[26]	21例服用利伐沙班的NVAF患者；15 mg·qd^-1，连续服用≥18 d	TRAP	56.15	8.53^*（7 d后）
[27]	14例服用利伐沙班的NVAF患者；15 mg·qd^-1或20 mg·qd^-1，连续服用≥7 d	凝血酶	69.55±32.15	44.79±34.97^*（7 d后）
[28]	6名健康志愿者，与递增浓度的利伐沙班混合	TF	78.00±5.00	77.50±1.60^*体外试验

参考文献	研究对象	CD62P		PAC-1/（ng·L^-1）
参考文献	研究对象	用药前	用药后	用药前	用药后
[39]	100例服用利伐沙班的NVAF患者，15 mg·d^-1 50例，20 mg·d^-1 50例	（43.4±2.1）ng·L^-1 （43.8±2.0）ng·L^-1	（23.6±3.1）ng·L^-1* （31.7±2.8）ng·L^-1*
[40]	60例服用利伐沙班的DVT患者	（1.95±0.27）μmol·L^-1	（0.85±0.13）μmol·L^-1*
[41]	41例服用利伐沙班的DVT患者	（1.96±0.29）ng·L^-1	（0.88±0.13）ng·L^-1*
[42]	21例服用利伐沙班的VTE患者	（24.6±6.7）ng·L^-1	（21.8±8.6）ng·L^-1
[43]	21例服用利伐沙班20 mg·qd^-1超过6周的AF患者	（161.2±51.8）ng·mL^-1	（155.8±71.6）ng·L^-1
[16]	89例服用利伐沙班5 mg·bid^-1的2型糖尿病患者	（109.8±37）ng·L^-1	（102.9±37）ng·L^-1*
[17]	18例服用利伐沙班15或20 mg·qd^-1的NVAF患者	（40.05±18.06）ng·L^-1	（32.81±15.87）ng·L^-1*	16.16±13.79	10.38±8.35^*